Rise and shine, everyone, another busy day is on the way. We can tell because one short person had to hustle for the ride to the local schoolhouse while the other short one also had to scoot so as not to be late for gainful employment. As for us, we are foraging for interesting items and reaching out to interesting people. So, time to get cracking, yes? This can only mean the time has come to pick up a cup of stimulation and dig in. On that note, here are some tidbits. Hope you have a smashing day and, of course, do keep in touch …

The Third Point hedge fund, piloted by Daniel Loeb, owns a small stake in Celgene (CELG), betting that the proposed $74 billion sale of the company to Bristol-Myers Squibb (BMY) will be completed, according to Reuters. The previously undisclosed position illustrates how some prominent hedge funds are placing opposing bets on what would be the biggest-ever pharmaceutical acquisition. Starboard Value, which holds a small stake in Bristol-Myers, is urging shareholders to vote down the Celgene deal. Third Point fund has no plans to publicly agitate, Reuters says.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • Online intelligence briefings
  • Frequent opportunities to engage with veteran beat reporters and industry experts
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.

A roundup of STAT’s top stories of the day in science and medicine

Privacy Policy